Multicancer Screening Market Size, Share & Trends Analysis Report By Test Type (Laboratory Developed Tests (LDTs) and In-Vitro Diagnostics (IVDs)), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH)), Sample, Method, Cancer Type, Application, And End-User And Segment Forecasts, 2025-2034
Global Multicancer Screening Market Size is valued at USD 2.3 Bn in 2024 and is predicted to reach USD 9.7 Bn by the year 2034 at a 15.4% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- The global ageing population is more susceptible to cancer, driving the need for effective screening methods.
- Increasing healthcare expenditure, particularly in developed regions, facilitates greater access to advanced screening technologies and services.
- North America dominated the market and accounted for a global revenue share in 2024.
- Inadequate Knowledge of Multicancer Screening Tests and Too Expensive to Use in Preventive Care.
The increasing incidence of cancer and the requirement for early diagnosis diagnostics, which make simple disease management possible and thereby reduce the death rate, are the main drivers of market revenue growth. 2020 saw about 10 million cancer-related deaths worldwide, making it the leading cause of death. The most frequent cancers in terms of new cases in 2020 were breast, lung, colon and rectum, prostate, skin, and stomach.
Consequently, there is a peak in demand for MCEDS as cancer incidence rises. Multi-Cancer Early Detection (MCED) testing, a minimally invasive technology, can identify malignancies from many organ sites with just one test, reducing the number of operations and saving time.
Large-scale R&D for the creation of MCED is another element boosting market revenue growth. For instance, research to identify and validate novel biomarker combinations that detect various malignancies early was initiated in Singapore on July 8, 2022. For instance, the biotechnology business MIRXES Ptr Ltd. disclosed that Project CADENCE had started following the signing of a memorandum of agreement (Cancer Detected Early can be Cured). This project is the first large-scale clinical research project of its kind in the world, and it will enable the development of a multi-cancer early detection test for up to nine cancers with a high incidence and mortality rate, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
Competitive Landscape:
Some of the Multicancer Screening market players are:
- Agilent Technologies, Inc.
- Atara Biotherapeutics, Inc.
- Burning Rock DX
- Danaher Corporation
- Exact Sciences Corporation
- Hoffmann-La Roche Ltd
- Fulgent Genetics.
- Genecast Biotechnology Co., Ltd
- Guardant Health, Inc.
- Illumina, Inc.
- Konica Minolta, Inc.
- Laboratory Corporation of America Holdings.
- Myriad Genetics, Inc.
- Tempus
- Thermo Fisher Scientific Inc.
- Other market players.
Market Segmentation:
The Multicancer Screening market is segmented on the basis of test type, technology, sample, method, cancer type, application, and end-user. Test type segment includes Laboratory Developed Tests (LDTs) and In-Vitro Diagnostics (IVDs). The technology segment includes Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies. By sample, the market is segmented into Tissue, Blood, Saliva, Buccal Swabs, and Others.
The method segment includes DNA, RNA, and Proteins. By cancer type, the market is segmented as Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types. Application segment covers Clinical and Research. By end user, the market is categorized into Hospitals, Diagnostic and Clinical Laboratories, Academic and Research Institutions, and Other End Users
Based On End User, The Hospitals Segment Is Accounted As A Major Contributor In The Multicancer Screening Market
With the majority of market revenue, the hospitals segment dominated the entire market. The prevalence of specialized medical professionals and healthcare workers who are involved in diagnosis and treatment is responsible for this segment's dominance. Hospitals are used as a platform to inform and raise public knowledge of various illnesses and ailments. The target audience knows very little about MCED, a new technology. As a result, hospitals examine asymptomatic people for several types to facilitate therapy.
LDTs Segment Witness Growth At A Rapid Rate
Due to the fact that it offers testing for several cancers, the LDT category had the highest revenue share. Gene panels target the identification of hereditary malignancies, and rising public awareness of hereditary diseases is expediting demand for genetic testing that can identify cancers early and enhance patient survival rates.
In The Region, The Europe Multicancer Screening Market Holds Significant Revenue Share
In Europe, the use of multi-cancer early detection has expanded in industries including hospitals, labs, diagnostic centers, and other significant market developments. The global market expansion in Europe is anticipated to be encouraged by the rising population, which is linked to a greater vulnerability to cancer-related chronic diseases and the economical diagnosis of chronic diseases in rural areas.
The market has grown significantly as a result of the increasing number of instances in Europe. For instance, according to a 2019 article by Eurostat, among the EU Member States, Hungary and Croatia had the highest standardized death rates for cancer, each with at least 300 per 100 000 residents. Due to these reasons, the European Union has started and intensified its attention on regional multi-cancer early detection programs.
Recent Developments:
- In June 2022, Roche introduced the BenchMark ULTRA PLUS system, a cutting-edge tool for cancer diagnostics that facilitates prompt and precise patient care. The BenchMark ULTRA PLUS tissue staining system provided a streamlined process, improved testing efficiency, and integrated ecologically friendly characteristics. This enabled pathologists to provide doctors and patients with accurate and timely results of superior quality.
Multicancer Screening Market Report Scope:
| Report Attribute | Specifications |
| Market size value in 2024 | USD 2.3 Bn |
| Revenue forecast in 2034 | USD 9.7 Bn |
| Growth rate CAGR | CAGR of 15.4% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ Billion, and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Test Type, Technology, Sample, Method, Cancer Type, Application, And End-User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock DX, Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Fulgent Genetics., Genecast Biotechnology Co., Ltd, Guardant Health, Inc., Illumina, Inc., Konica Minolta, Inc., Laboratory Corporation of America Holdings., Myriad Genetics, Inc., Tempus, and Thermo Fisher Scientific Inc. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Multicancer Screening Market-
Multicancer Screening Market By Test Type-
- Laboratory Developed Tests (LDTs)
- In-Vitro Diagnostics (IVDs)
Multicancer Screening Market By Technology-
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Fluorescence In-Situ Hybridization (FISH)
- Other Technologies
Multicancer Screening Market By Sample-
- Tissue
- Blood
- Saliva and Buccal Swab
- Others
Multicancer Screening Market By Method -
- DNA
- RNA
- Proteins
Multicancer Screening Market By Cancer Type-
- Breast and Gynecologic
- Gastrointestinal
- Endocrine
- Genitourinary
- Skin
- Brain/Nervous System
- Sarcoma
- Hematological Malignancies
- Lung
- Head and Neck
- Other Cancer Types
Multicancer Screening Market By Application -
- Clinical
- Research
Multicancer Screening Market By End User -
- Hospitals
- Diagnostic and Clinical Laboratories
- Academic and Research Institutions
- Other End Users
Multicancer Screening Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Multicancer Screening Market Size is valued at USD 2.3 Bn in 2024 and is predicted to reach USD 9.7 Bn by the year 2034
Multicancer Screening Market expected to grow at a 15.4% CAGR during the forecast period for 2025-2034
Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock DX, Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, F
Test Type, Technology, Sample, Method, Cancer Type, Application, and End-User are the key segments of the Next-Generation Lithography Materials Market
North America region is leading the Multicancer Screening Market